Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Patient perspectives and treatment regret after de‐escalated chemoradiation for human papillomavirus‐positive oropharyngeal cancer: Findings from a phase II trial
Ist Teil von
Head & neck, 2019-08, Vol.41 (8), p.2768-2776
Ort / Verlag
Hoboken, USA: John Wiley & Sons, Inc
Erscheinungsjahr
2019
Link zum Volltext
Quelle
Wiley Online Library Journals
Beschreibungen/Notizen
Background
We evaluated priorities, expectations, and regret among patients treated on a phase II trial of de‐escalated chemoradiation for human papillomavirus (HPV)‐positive oropharyngeal cancer.
Methods
Eligibility included stage III/IV squamous cell carcinoma of the oropharynx, p16‐positivity, age ≥18 years, and Zubrod score 0‐1. Participants were surveyed with validated measures evaluating their treatment experience.
Results
Twenty‐four of 27 (89%) patients participated with a median follow‐up of 24 months. Twenty‐three subjects (96%) selected “being cured” or “living as long as possible” as top priority. No patient reported any regret about the decision to enroll on a de‐escalation protocol. Sixteen participants (67%) found retrospectively reported long‐term swallowing function to be either better than or as originally expected.
Conclusions
These data offer a baseline landscape of perspectives and priorities for patients treated with de‐escalation for HPV‐positive oropharyngeal carcinoma and provide support to the fundamental premise underlying ongoing efforts to establish a new standard of care.